Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study ; volume:32 ; number:10 ; day:7 ; month:10 ; year:2024 ; pages:1-7 ; date:10.2024
Supportive care in cancer ; 32, Heft 10 (7.10.2024), 1-7, 10.2024
- Urheber
-
Negoro, Yutaka
Maeda, Taichi
Igarashi, Hiroyuki
Shigemori, Mina
Tanaka, Toshihiro
Ito, Yukio
Tanizawa, Norihiko
Nishikawa, Shota
Ogawa, Jyunya
Kamitani, Yukio
Watanabe, Kyohei
Tsukamoto, Hitoshi
Goto, Nobuyuki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-024-08910-8
- URN
-
urn:nbn:de:101:1-2501082102295.568627858790
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Negoro, Yutaka
- Maeda, Taichi
- Igarashi, Hiroyuki
- Shigemori, Mina
- Tanaka, Toshihiro
- Ito, Yukio
- Tanizawa, Norihiko
- Nishikawa, Shota
- Ogawa, Jyunya
- Kamitani, Yukio
- Watanabe, Kyohei
- Tsukamoto, Hitoshi
- Goto, Nobuyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma